hexagon-bio
(2)
Maureen Hillenmeyer
Maureen Hillenmeyer is the founder and CEO of Hexagon Bio, a Menlo Park drug-discovery company that mines the genomes of fungi for hidden small molecules and engineers yeast to brew them into potential medicines. A former competitive swimmer turned computational biologist, she holds a PhD in biomedical informatics from Stanford and built the company out of a Stanford research program she led, raising more than $270 million to turn DNA sequence data into cancer and infectious-disease therapeutics.
Sofia Touami
Sofia Touami, Ph.D., is the Chief Business Officer of Lycia Therapeutics, a South San Francisco biotech pioneering lysosomal targeting chimeras (LYTACs) - a platform invented by Nobel laureate Carolyn Bertozzi to degrade disease-causing extracellular proteins. A trained organic chemist who earned her Ph.D. at Stanford and did postdoctoral work at The Scripps Research Institute, Touami has built a career as one of biotech's sharpest dealmakers, having orchestrated major transactions including Frontier Medicines' landmark global collaboration with AbbVie before joining Lycia in July 2023. She helped close Lycia's oversubscribed $106.6 million Series C in May 2024, positioning the company to bring its LYTAC-based autoimmune therapies into clinical trials.